Greenwich LifeSciences, Inc. (GLSI)
| Market Cap | 447.70M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.86M |
| Shares Out | 12.85M |
| EPS (ttm) | -0.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $33.79 |
| Previous Close | $33.91 |
| Change ($) | -0.12 |
| Change (%) | -0.35% |
| Day's Open | 34.01 |
| Day's Range | 33.20 - 35.25 |
| Day's Volume | 59,519 |
| 52-Week Range | 3.26 - 158.07 |
The top-performing IPO of 2020 is a high-risk, high-reward opportunity, with one drug in its pipeline and one disease in its sights. Is it worth investing in now?
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Hires Industry Expert Dr. Christine Fischette to Lead Business Development & Advise on Commercialization
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting
The drop came despite the clinical-stage biotech announcing good news over the weekend.
STAFFORD, Texas--(BUSINESS WIRE)--GLSI's Immune Response Data Shows Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer
STAFFORD, Texas--(BUSINESS WIRE)--GLSI's Immune Response Data Shows Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer
The company reported positive data for its cancer immunotherapy candidate GP2.
Greenwich Lifesciences Inc (NASDAQ: GLSI) shares are trading higher by more than 15% after the company reported a robust immune response from its Phase 2b data supporting the GP2 clinical outcome of 0% ...
Greenwich LifeSciences Inc (NASDAQ: GLSI) has announced the abstract results of the final 5-year immune response data of the Phase 2b trial at the 2021 AACR Annual Meeting. The company plans to publish...
STAFFORD, Texas--(BUSINESS WIRE)--GLSI Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic Breast Cancer Recurrences Over 5 Years Follow-up
Greenwich LifeSciences is advancing cancer treatments with life-changing potential, and recent developments should boost GLSI stock's value. The post Greenwich LifeSciences Is Both a Sound Investment an...
New York, New York--(Newsfile Corp. - March 24, 2021) - Levi & Korsinsky announces it has commenced an investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) concerning possible breaches of fiduci...
On December 8, 2020, Greenwich LifeSciences (NASDAQ: GLSI) share price closed at $5.20 per share. Greenwich LifeSciences published its 5-year breast cancer data from a Phase IIb trial at the San Antonio...
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) is a biopharmaceutical company that is developing GP2, an immunotherapy to prevent breast cancer recurrences in certain patients. The stock skyrocketed nearly...
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Updates 2021 Timeline & Announces Two Upcoming Presentations at the American Association for Cancer Research Annual Meeting
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences CEO to be Interviewed Live on Benzinga's Power Hour - Interview will air on Thursday, March 11, 2021 at 12:30 pm EST
Investors cheered an important new hire.
GLSI stock is skyrocketing again on Monday after the company appointed Dr. Jaye Thompson to run its Phase 3 clinical trials. The post GLSI Stock: Why Greenwich LifeSciences Is Skyrocketing Today appeare...
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Hires Industry Expert, Dr. Jaye Thompson, to Manage Phase III Clinical Trial for Recurring Breast Cancer
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at Multiple Investor Conferences, Including H.C. Wainwright Global Life Sciences and Bio-Europe Spring Conferences
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Acceptance of Two Abstracts at Upcoming Major Cancer Conference
New York, New York--(Newsfile Corp. - February 2, 2021) - Levi & Korsinsky announces it has commenced an investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) concerning possible breaches of fidu...
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Exercise and Closing of Underwriter's Over-Allotment Option
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences CEO Interview to Air on Bloomberg International on the RedChip Money Report
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at B. Riley Securities and BIO CEO & Investor Conferences
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Participate in Multiple Virtual Investor Conferences During 2021 JP Morgan Healthcare Week
New York, New York--(Newsfile Corp. - January 5, 2021) - Levi & Korsinsky announces it has commenced an investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) concerning possible breaches of fiduc...
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences' LD Micro Presentation Replay Now Available
Breast cancer is the second leading cause of death of women in the U.S. alone. Given the prevalence of the disease, it's no surprise that numerous pharmaceutical and biotech companies are searching for ...
A lot of buzz-generating IPOs have more than tripled in 2020, but you probably don't know the top U.S. debutante that has soared 583% this year.
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Ring Nasdaq Opening Bell on December 28
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. Announces Closing of Public Offering of Common Stock
The company announced the pricing of a public offering of common stock.
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. Prices $26.4 Million Upsized Public Offering of Common Stock
New York, New York--(Newsfile Corp. - December 16, 2020) - Levi & Korsinsky announces it has commenced an investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) concerning possible breaches of fid...
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Option Agreement for Pre-clinical Coronavirus Vaccine Candidates
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Poster Presentation on Its GP2 Phase III Clinical Trial Design for Recurring Breast Cancer
Immutep (NASDAQ: IMMP) shares are trading higher on Thursday after the company reported a statistically significant survival benefit for key patient groups in its ongoing Phase IIb AIPAC study in metast...
Greenwich LifeSciences made investors rich overnight. Is there any growth left in this breast cancer treatment developer?
Greenwich LifeSciences (NASDAQ: GLSI) is currently up 62.87% to a price of $84.29. The stock's volume is currently 2.41 million, which is roughly 375.86% of its recent 30-day volume average of 640.72 th...
You don't have to be a pandemic fighter to have a big victory for investors.
The stock price of Greenwich Lifesciences Inc (NASDAQ: GLSI) increased 857.74% as it went from $5.20 at the previous close to $49.79 (3:42 PM ET) today. This is why it happened.
Greenwich LifeSciences (NASDAQ: GLSI) shares spiked 1,900% higher Wednesday after the company shared the poster for the GP2 Phase 2b clinical trial final efficacy analysis that was presented Wednesday a...
Investors had a field day with Greenwich LifeSciences on Wednesday after the tiny biotech company skyrocketed as much as 2,941% on encouraging phase 2b data for its breast cancer immunotherapy treatment...
GLSI stock is soaring Wednesday after Greenwich LifeSciences shared promising results from its breast cancer immunothrapy. The post GLSI Stock: Why Greenwich LifeSciences Is Up 2,000% Today appeared fir...
Shares of Greenwich LifeSciences Inc. were launched to a more than fourfold gain in very active midday trading Wednesday, after the Texas-based biopharmaceutical company displayed upbeat results of a Ph...
Greenwich LifeSciences's (NASDAQ: GLSI) stock has been rising Wednesday, up 350.11% to a price of $19.85. Wednesday the stock has been traded at a volume of 2.32 million, about 10387.18% of its recent 3...
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Poster Presentation of Five Year Data for GP2 Phase IIb Clinical Trial, Showing 0% Recurrence of Breast Cancer
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces New Manufacturing Agreement for its Planned Phase III Clinical Trial and Enters into Lease for Office and Lab Space
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at the Annual LD Micro Main Event
About GLSI
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Staffo... [Read more...]
| Industry Biotechnology | IPO Date Sep 25, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol GLSI |